OricPharma logo
Publications
GLUCOCORTICOID RECEPTOR (GR) ANTAGONIST PROGRAM: ORIC-101
ORIC publications
Initial results from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer
Poster presented at: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021. Poster # P041
Biomarker results supporting selection of RP2D from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Poster presented at: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021. Poster # P015
Initial Results from a Phase 1b Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with advanced Solid Tumors
Poster Presented at: 2021 ASCO Annual Meeting, June 4-8, 2021. Abstract #2553
Biomarker Results Supporting Selection of RP2D from a Phase 1b Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors
Poster Presented at: 2021 ASCO Annual Meeting, June 4-8, 2021. Abstract #3110
GR Antagonist ORIC-101 Overcomes GR-mediated Resistance to the Combination of AR and AKT Inhibition in Preclinical Prostate Cancer Cell Lines
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract #1420
ORIC-101 overcomes GR-driven resistance to AR degradation in castration-resistant prostate cancer models
Poster presented at: 2020 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 24-25, 2020. Poster PD-050
ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #4120.
ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #4121.
ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #4123.
An open-label Phase 1b study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
Poster presented at: 2020 Genitourinary Cancers Symposium; February 13–15, 2020; San Francisco, CA, USA. Abstract #TPS253.
ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in TNBC
Poster presented at: 2019 San Antonio Breast Cancer Symposium; December 14, 2019; San Antonio, TX, USA. Abstract #2507.
ORIC-101 overcomes glucocorticoid-driven resistance to androgen receptor inhibition in CRPC
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A10.
CD73 INHIBITOR PROGRAM: ORIC-533
ORIC publications
Blocking Adenosine Production with ORIC-533, a CD73 Inhibitor with Best-In-Class Properties, Reverses Immunosuppression in High-AMP Environments
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract # LB-163
CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cell activation
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #1023
An orally bioavailable inhibitor of CD73 reverts intratumoral immunosuppression and promotes anti-tumor response
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #LB-115
Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production
Presented at: 2020 American Association for Cancer Research; April 27, 2020. Abstract #1242, presentation 1037.
Intratumoral immunosuppression is reversed by blocking adenosine production with an oral inhibitor of CD73
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A19.
PRC2 INHIBITOR PROGRAM: ORIC-944
ORIC publications
ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Demonstrates Robust In Vivo Activity in Prostate Cancer Models
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract #1131
EGFR/HER2 INHIBITOR PROGRAM: ORIC-114
ORIC publications
ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer
Poster presented at: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021. Poster # P234
ORIC-114, a Brain Penetrant, Orally Bioavailable, Irreversible Inhibitor Selectively Targets EGFR and HER2 Exon 20 Insertion Mutants and Regresses Intracranial NSCLC Xenograft Tumors
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract #1466